Delivering a CRISPR-Cas-derived adenine base editor as a short-lived protein-guide RNA complex enabled efficient PCSK9 ...
The US FDA has accepted Intellia Therapeutics’ application for lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) and ...
Global adoption growing with more than 400 institutions across 33 countries ordering DNA constructs up to 49.1 kb, with ...
Delivering CRISPR-Cas9 as mRNA in lipid nanoparticles preserved the fitness and erythroid potential of edited human ...
Great to see our founder Jens-Ole Bock speaking at this week's CRISPR Gene Editing Hands-on Workshop... Clinical: Expanded Access Takes SNIPR001 Beyond... CRISPR-Cas base editing altered HTT RNA ...
Delivering a CRISPR-Cas-derived adenine base editor as a short-lived protein-guide RNA complex... CMN Intelligence Q2 2026 Update: 300+ CRISPR -... Sep. 10, 2026 CMN Intelligence has released the CMN ...
Precision BioSciences reported progress with its CRISPR-Cas–based ARCUS gene editing therapy PBGENE-DMD, designed to excise dystrophin exons 45–55 and restore near full-length dystrophin expression.
Researchers have used a novel CRISPR-Cas library to identify essential microRNAs in prostate cancer cells, revealing miR-483-3p as a key regulator of cell survival. The study found that disrupting ...
In vivo genome editing is entering an important new phase. Advances in editing technologies, delivery platforms and translational science are bringing the prospect of one-time, directly administered ...
The Federation of American Societies for Experimental Biology (FASEB) conference on Genome Engineering kicks off one month from now in Rome, Italy. The Federation of American Societies for ...
(Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and ...
Intellia Therapeutics has reported positive three-year follow-data from the ongoing Phase 1/2 trial of lonvo-z (formerly known as NTLA-2002) in patients with hereditary angioedema. The data show that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results